+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?



Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?



American Journal of Cardiology 104(5 Suppl): 4c



Oral antiplatelet drugs are central in the management of acute coronary syndromes, including unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention. However, the mechanisms that confer the benefits of these agents also increase bleeding risk. Thus, the selection of appropriate pharmacotherapy requires close attention to the delicate balance between reducing the risk of ischemic events and minimizing bleeding risk. A critical review of the 2007 guidelines in these areas and new clinical data with currently available and soon-to-be-approved antiplatelet agents are presented.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054780424

Download citation: RISBibTeXText

PMID: 19695354

DOI: 10.1016/j.amjcard.2009.06.019


Related references

Comparison of outcomes of patients ≥ 80 years of age having percutaneous coronary intervention according to presentation (stable vs unstable angina pectoris/non-ST-segment elevation myocardial infarction vs ST-segment elevation myocardial infarction). American Journal of Cardiology 108(10): 1395-1400, 2011

Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a real-life setting: the final report (J-PLACE Final). Cardiovascular Intervention and Therapeutics 31(2): 101-113, 2016

Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study. International Journal of Cardiology 160(3): 213-214, 2012

Primary percutaneous coronary intervention for patients presenting with ST-segment elevation myocardial infarction: process improvement in a rural ST-segment elevation myocardial infarction receiving center. Progress in Cardiovascular Diseases 53(3): 202-209, 2010

Primary percutaneous coronary intervention without on-site cardiac surgery backup in unselected patients with ST-segment-elevation myocardial infarction: the Rivoli ST-segment elevation myocardial infarction (RISTEMI) registry. Cardiovascular Revascularization Medicine 14(1): 9-13, 2013

Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. Journal of the American College of Cardiology 58(15): 1592-1599, 2011

Recent update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: role of antiplatelet therapy. Clinical Cardiology 27(3): 119-120, 2004

Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction. Critical Pathways in Cardiology 9(2): 55-81, 2010

Long-term results after very early percutaneous coronary intervention in unstable angina and non-ST-segment elevation myocardial infarction. European Heart Journal 22(Abstract Suppl.): 618, 2001

Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circulation. Cardiovascular Interventions 2(4): 330-338, 2009

Risk and clinical predictors for patients with unstable angina and non-ST segment elevation myocardial infarction post early percutaneous coronary intervention. 2008

Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Jacc. Cardiovascular Interventions 7(6): 613-614, 2014

Symptom-Onset-To-Balloon Time, ST-Segment Resolution and In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in China: From China Acute Myocardial Infarction Registry. American Journal of Cardiology 118(9): 1334-1339, 2016

Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina pectoris or non-ST-elevation myocardial infarction vs ST-elevation myocardial infarction) on 2-year outcomes in patients undergoing percutaneous coronary intervention. Journal of Interventional Cardiology 31(1): 5-14, 2018

Coronary plaque rupture with subsequent thrombosis typifies the culprit lesion of non-ST-segment-elevation myocardial infarction, not unstable angina: non-ST-segment-elevation acute coronary syndrome study. Heart and Vessels 32(3): 241-251, 2017